Merck KGaA, Feinstein Institute deal

Merck's Merck Serono S.A. subsidiary partnered with the institute to develop antibodies to treat systemic lupus erythematosus (SLE). Merck Serono will fund a research program at the institute on antibodies that inhibit proteins responsible for inflammation in SLE. Merck Serono will also be responsible for the development and commercialization of antibodies resulting from the deal. The partners did not disclose details. ...